De novo lipogenesis has been implicated in prostate carcinogenesis, and blood levels of specific saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs) could reflect activity of this pathway. We used gas chromatography to measure blood SFA and MUFA levels in prediagnostic samples from 476 incident prostate cancer cases (1982)(1983)(1984)(1985)(1986)(1987)(1988)(1989)(1990)(1991)(1992)(1993)(1994)(1995) in the Physicians' Health Study and an equal number of controls matched on age and smoking status. Five tagging polymorphisms in the fatty acid synthase (FASN) gene (rs1127678, rs6502051, rs4246444, rs12949488, and rs8066956) were related to blood SFA and MUFA levels. Conditional logistic regression was used to estimate the rate ratios, with 95% confidence intervals, of prostate cancer across quintiles of blood fatty acid levels. The polymorphisms rs6502051 and rs4246444 were associated with lower levels of 14:1n-5, 16:1n-7, and 18:1n-9. Blood levels of 16:1n-7 were associated with higher prostate cancer incidence, with rate ratios for men in increasing quintiles of 1.00, 1.40, 1.35, 1.44, and 1.97 (95% confidence interval: 1.27-3.06; P trend = 0.003). Furthermore, 16:1n-7 levels were positively related to incidence of high-grade (Gleason score ≥7) tumors (rate ratio Q5-Q1 = 3.92; 95% confidence interval: 1.72-8.94) but not low-grade tumors (rate ratio Q5-Q1 = 1.51; 95% confidence interval: 0.87-2.62) (P heterogeneity = 0.02). Higher activity of enzymes involved in de novo lipogenesis, as reflected in blood levels of 16:1n-7, could be involved in the development of high-grade prostate cancer. biomarkers; epidemiology; fatty acids; nutrition; prostate cancer Abbreviations: CI, confidence interval; FASN, fatty acid synthase; MUFA, monounsaturated fatty acids; SFA, saturated fatty acids; SNP, single-nucleotide polymorphism.
Increasing evidence suggests a role of de novo synthesis of fatty acids in the development of prostate cancer, particularly of clinically relevant tumors. For example, fatty acid synthase (FASN) is overexpressed in prostate cancer (9) , and its expression level is positively correlated to tumor grade (9, 10) . In addition, we have found that single-nucleotide polymorphisms (SNPs) in FASN are related to lower prostate cancer risk and lower disease-specific mortality rate (11) . To gain further insights into the role of fatty acid metabolism in prostate cancer, we conducted a prospective study to examine whether common polymorphisms in FASN were associated with blood levels of several SFAs and MUFAs and whether these fatty acids were related to prostate cancer risk in men followed up for more than 20 years.
MATERIALS AND METHODS

Study population
This study is based on the Physician's Health Study (12, 13) , a randomized trial of aspirin and β-carotene in the prevention of heart disease and cancer among 22,071 male physicians who were 40-84 years of age in 1982. Men were excluded from the study if they had a history of myocardial infarction, stroke, transient ischemic attack, unstable angina, cancer (except nonmelanoma skin cancer), renal or liver disease, peptic ulcer, or gout; had a contraindication to the use of aspirin; or were users of aspirin, platelet-active medications, or vitamin A supplements. The aspirin component of the trial was terminated early in 1988 because of the benefits of aspirin on myocardial infarction (12) . The β-carotene component of the trial was terminated as scheduled in 1995 (13) . Written, informed consent was obtained from each participant, and the study was approved by the Human Research Committee at Brigham and Women's Hospital, Boston, Massachusetts.
Prerandomization blood specimens were obtained from 14,916 participants (68%), processed after overnight delivery, and stored at −82°C (14) . The present report is restricted to men diagnosed with prostate cancer after having provided the baseline sample and their matched controls. Follow-up was more than 99% complete for morbidity and 100% complete for mortality.
Selection of cases and controls
Whenever a participant reported a diagnosis of prostate cancer, we requested hospital records and pathology reports for review by study physicians from the Physicians' Health Study Endpoints Committee to confirm the diagnosis of prostate cancer and determine the tumor stage and grade at diagnosis. Histological grade was recorded according to the Gleason scoring system. Tumor stage was recorded according to the tumor-node-metastasis (TNM) staging system or was converted from the modified Whitmore-Jewett classification scheme (for prostate cancer cases diagnosed during the early years of Physicians' Health Study follow-up). Using the risk set sampling method, we selected a control subject for each confirmed case among the men in the entire risk set who had provided a blood sample and did not have a partial or total prostatectomy or prostate cancer at the time of the case's diagnosis. Controls were individually matched to cases by baseline age (±1 year for men ≤55 years of age and ±5 years for men >55 years of age) and smoking status (current, former, or never). Of the 758 cases accrued through 1995 in the entire study, 505 had provided a baseline blood sample that could be used for the determination of fatty acid levels. Cases and controls whose blood samples had been received ≥6 days after they were drawn were excluded from analyses, leaving 476 cases and their matched controls.
Laboratory analyses
Blinded samples from cases and their matched controls were processed and analyzed together to reduce any effect of interassay variability. Fatty acids were extracted from whole blood into isopropanol and hexane containing 50 mg of 2.6di-tert-butyl-p-cresol as an antioxidant. Fatty acids were transmethylated with methanol and sulfuric acid, as previously described (2, 15, 16) . After esterification, the samples were evaporated, and the fatty acids were redissolved in iso-octane and quantified by gas-liquid chromatography on a fused silica capillary cis/trans column (SP2560, Supelco, Belafonte, Pennsylvania). Peak retention times were identified by injecting known standards (Nu-Chek Prep, Inc., Elysian, Minnesota) and were analyzed with ChemStation A.08.03 software (Agilent Technologies, Lexington, Massachusetts). The fatty acid levels in each sample were expressed as the percentage of total fatty acids. Coefficients of variation for all fatty acid peaks were measured by analyzing blinded quality control samples randomly distributed throughout the study samples. The coefficients of variation were 9% for myristic acid (14:0), 0.9% for palmitic acid (16:0), 1.3% for stearic acid (18:0), 15.7% for myristoleic acid (14:1n-5), 2.9% for palmitoleic acid (16:1n-7), and 0.3% for oleic acid (18:1n-9). Although we could not directly assess whether long-term storage and freezing affected the fatty acid measurements, n-3 and n-6 polyunsaturated fatty acids have moderately high reliability coefficients (0.66 and 0.53, respectively) and minimal oxidation in serum samples stored for up to 12 years at −80°C (17). 
FASN SNPs and genotyping
Using the HapMap database (National Center for Biotechnology Information Build 35) and the Web-based Tagger application (http://broad.harvard.edu/mpg/tagger/), we identified 5 SNPs that captured genetic variation (with R 2 > 0.80) within FASN and 5 kb upstream and downstream. SNPs with a minor allele frequency less than 5% in the HapMap CEU population (Utah residents with ancestry from northern and western Europe) were excluded. DNA was extracted from whole blood. Genotyping was performed with iPLEX (Sequenom, Inc., San Diego, California) matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry technology at the Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts. All SNPs had genotype completion rates greater than 91%, which did not differ between cases and controls.
Statistical analyses
We calculated median values and proportions of the baseline characteristics of case and control subjects. To evaluate whether these characteristics differed between cases and controls, categorical variables were tested with the McNemar test, and continuous variables were tested with the Wilcoxon signrank test. We examined the relation between tagging SNPs in FASN and blood levels of 14:0, 16:0, 18:0, 14:1n-5, 16:1n-7, and 18:1n-9 by using linear regression models adjusted for baseline age and smoking status-the matching variables for selecting case-control pairs.
To estimate the association between blood levels of SFAs and MUFAs and prostate cancer, we first divided cases and controls into 5 groups according to quintiles of fatty acid levels among the controls. We then used conditional logistic regression to estimate the rate ratio of prostate cancer (with 95% confidence interval) in a given quintile of fatty acid level in relation to the lowest quintile. We considered the potential confounding effects of baseline characteristics by adding to the initial model terms for variables associated with prostate cancer and fatty acid levels at P < 0.20 and by evaluating whether the addition of these variables changed the initial fatty acid estimates by >10%. Addition of the variables meeting these criteria (height, body mass index, and blood fatty acids previously related to prostate cancer in this cohort (4, 5)) did not change the initial fatty acid estimates substantially, and therefore further adjustment for these variables was not performed.
We fitted regression models in subgroups defined by tumor stage and grade at diagnosis and estimated the significance of differences in stratum-specific estimates by using polytomous logistic regression. Last, because we had found previously that body mass index (weight (kg)/height 2 (m 2 )) modified the relation between FASN polymorphisms and prostate cancer risk and death (11), we evaluated body mass index as an effect modifier of the relation between fatty acids and prostate cancer risk. Tests for linear trend were conducted in all models, with the median fatty acid levels in each quintile used as a continuous variable. All statistical analyses were performed in SAS version 9.1 (SAS Institute Inc., Cary, North Carolina). Results were considered to be statistically significant when P < 0.05 (2-tailed).
RESULTS
At baseline, men subsequently diagnosed with prostate cancer had higher blood levels of total MUFAs than controls but had no other significant differences in blood levels of other major fatty acid groups or other baseline characteristics ( Table 1 ). The median time between enrollment and prostate cancer diagnosis was 9 years, ranging from 1 month to 13 years. Ninety-five percent of the cases (n = 451) were diagnosed at least 2 years after enrollment, and 85% (n = 404) were diagnosed at least 5 years after enrollment. Most prostate cancer cases presented as localized and low-grade disease. Two thirds of the cases were diagnosed after the widespread use of prostate-specific antigen screening became routine.
Blood fatty acid levels were, in general, positively correlated with each other ( Table 2 ). Correlations were strongest for those most closely related within the de novo lipogenesis pathway (14:0 and 14:1n-5; 16:0 and 16:1n-7). Stearic acid (18:0) was the exception to this pattern, being inversely related to other fatty acids.
Of the 5 FASN SNPs evaluated, 3 were associated with blood levels of at least 1 SFA or MUFA. Men who were variant allele homozygotes in rs6502051 (G>T) and rs4246444 (C>A) had lower blood levels of myristoleic (14:1n-5), palmitoleic (16: 1n-7), and oleic (18:1n-9) acids than did the wild-type homozygotes. In addition, variant allele homozygotes in rs12949488 had significantly higher blood levels of myristic acid (14:0) than did wild-type homozygotes ( Table 3 ).
Blood levels of SFAs were not significantly related to prostate cancer incidence (Table 4 ). However, incidence of prostate cancer increased with increasing blood levels of MUFAs (Table 5 ). Blood levels of myristoleic (14:1n-5), palmitoleic (16:1n-7), and oleic (18:1n-9) acids were associated with higher incidence of prostate cancer, and the association was strongest for palmitoleic acid. Men in the highest quintile of blood palmitoleic acid levels were twice as likely to develop prostate cancer as men in the bottom quintile of blood levels for this fatty acid.
Because some men were diagnosed with prostate cancer shortly after enrollment, we evaluated whether exclusion of cases identified during the first 2 or 5 years of follow-up affected the results (Web Table 1 , available at http://aje. oxfordjournals.org/). In addition, we examined whether the associations between fatty acids and prostate cancer differed significantly between cases diagnosed during the first and the second halves of the follow-up period (Web Table 2 ). The rate ratios comparing top with bottom quintiles of 16:1n-7 were 1.87 (95% confidence interval (CI): 1.19, 2.92), 2.04 (95% CI: 1.26, 3.29), and 2.57 (95% CI: 1.34, 4.95) after exclusion of the first 2, 5, and 9 years of follow-up, respectively. There was no evidence of heterogeneity according to follow-up time (P heterogeneity = 0.63).
We also assessed the ratio of palmitoleic to palmitic acid (16:1n-7/16:0) as an index of stearoyl CoA desaturase activity and observed rate ratios of prostate cancer in increasing quintiles of estimated stearoyl CoA desaturase activity of 1.00, 1.42 (95% CI: 0.91, 2.21), 1.34 (95% CI: 0.85, 2.12), 1.51 (95% CI: 0.97, 2.35), and 1.96 (95% CI: 1.26, 3.06) (P trend = 0.004). This association was nearly identical to that observed for palmitoleic acid. We also examined the ratio of We found no appreciable differences in the association between individual fatty acids and prostate cancer when stratified by stage at diagnosis (Table 6 ). However, when stratified by grade (Table 6) , the association between blood palmitoleic acid levels and prostate cancer incidence was limited to highgrade tumors (Gleason score ≥7) (P heterogeneity = 0.02). When blood levels of myristoleic (14:1n-5), palmitoleic (16:1n-7), and oleic (18:1n-9) acids were included simultaneously in the same model, the relation of palmitoleic acid (16:1n-7) with high-grade tumors became stronger. The adjusted rate ratios of Gleason ≥7 prostate cancer comparing top with bottom quintiles of fatty acids in this model were 0.91 (95% CI: 0.35, 2.39; P trend = 0.58) for myristoleic acid, 4.32 (95% CI: 1.59, 11.8; P trend = 0.001) for palmitoleic acid, and 1.04 (95% CI: 0.42, 2.55; P trend = 0.96) for oleic acid. The association with palmitoleic acid persisted even after adjustment for height, body mass index, fatty acids previously related to prostate cancer risk in this cohort (linoleic, long chain n-3, and 18:2trans), and fasting status. In this model, the adjusted rate ratio of Gleason ≥7 prostate cancer comparing top with bottom quintiles of palmitoleic acid was 3.73 (95% CI: 1.23, 11.3; P trend = 0.009). There was no evidence that the relation between palmitoleic acid and prostate cancer was modified by body mass index (P interaction = 0.44).
DISCUSSION
We found that blood levels of palmitoleic acid (16:1n-7) were related to prostate cancer incidence in this prospective study. The association for palmitoleic acid was strongest for Gleason ≥7 tumors, with a 4-fold greater incidence for men in the top quintile of blood palmitoleic acid levels than for men in the lowest quintile. Furthermore, we found that 2 tagging SNPs in FASN (rs6502051 and rs4246444) were significantly related to lower blood levels of myristoleic (14: 1n-5), palmitoleic (16:1n-7), and oleic (18:1n-9) acids. These results, together with our previous findings that the same 2 SNPs that predict lower blood levels of MUFAs in the present study are also associated with lower risk of death due to prostate cancer (11) , strongly suggest that de novo lipogenesis, acting through palmitoleic acid, could be an important metabolic pathway involved in prostate carcinogenesis. Our findings lend further support to the hypothesis that de novo lipogenesis is important in prostate carcinogenesis. FASN is overexpressed in prostate tumors as compared with normal prostate tissue, both at the mRNA level and the protein level (9, 10, 18, 19) . In addition, the expression level of FASN in prostate tumors is positively correlated to tumor grade (9, 10, 20) , is highest in metastatic tumors (10, 20) , and is related to disease-specific mortality rate among overweight men with prostate cancer (11) . Inhibition of FASN by chemical inhibitors (cerulenin and C75) or by RNA interference-selective gene silencing leads to a rapid decline in fatty acid synthesis, associated with growth inhibition and cell apoptosis (20) (21) (22) (23) (24) (25) . The growth arrest response triggered by FASN inhibition has been attributed to altered lipid production (21, 26) . Similarly, selective inhibition of acetyl CoA carboxylase (ACC1) with specific gene silencing by RNA interference in human LNCaP cells (25) is correlated to a decline in fatty acid synthesis, growth arrest, and induction of apoptosis associated with alteration of mitochondrial function. We have also reported that SNPs in FASN are related to prostate cancerspecific mortality rate (11) , and the direction of the association between FASN SNPs and prostate cancer mortality rate is in the same direction of their association with blood MUFAs in the present study. Specifically, the rate ratios for prostate cancer-specific death were 0.72 (95% CI: 0.55-0.95) for rs4246444 and 0.81 (95% CI: 0.64-1.03) for rs6502051. In addition, the rate ratio of advanced prostate cancer for rs6502051 was 0.77 (95% CI: 0.59-0.99). These 2 tagging SNPs were also associated with lower blood levels of 14:1n-5, 16:1n-7, and 18:1n-9 in the present study.
The results presented in this article, together with our previous findings (11) , suggest that there could be at least 3 non-mutually exclusive mechanisms linking FASN to prostate cancer. On one hand, rs8066956, which was related to FASN expression in tumor tissue (11) , might have a direct local effect on disease. Other variants in FASN could be operating at a systemic level. rs1127678 could increase incidence of clinically relevant disease by increasing body mass index (11)-itself a risk factor for disease-specific death in this cohort (27)-and its related metabolic abnormalities. Modulation of circulating 16:1n-7 levels (representing primarily adipose tissue and hepatic lipogenesis) might be an additional mechanism explaining the previously reported associations of rs6502051 and rs4246444 with prostate cancer incidence and disease-specific mortality rate. Experimental data suggest that 16:1n-7 behaves as a hormone in vivo (28) and stimulates cell proliferation in vitro (29) . There are some gaps in this picture, however, that require further study. It is not clear whether the hormone-like behavior of this fatty acid is present in humans (30, 31) , nor is it known whether its mitogenic effects are also present in prostate tissue in vivo. We also lacked data on other genes involved in de novo lipogenesis: acetyl CoA carboxylase (ACC1), fatty acid elongase (ELOVL6), and stearoyl CoA desaturase (SCD1). Moreover, the main metabolic product of FASN 16:0 was not related to the tagging SNPs evaluated, and though it was positively related to prostate cancer incidence, this association was not statistically significant. Further examination of this metabolic pathway is needed to clarify its relation to prostate cancer.
In agreement with our findings, most previous studies have found no relation between levels of myristic (14:0) (32, 33) , palmitic (16:0) (14, (33) (34) (35) (36) (37) , or stearic (18:0) (33-38) acids and prostate cancer risk. The exceptions have been reports from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) trial (35) and Norway's Janus serum bank (38) that indicated higher prostate cancer risk with increased myristic acid levels, reports from Janus (38) and the European Prospective Investigation into Cancer and Nutrition (EPIC) (32) that showed greater prostate cancer risk with elevated palmitic acid levels, and a report from EPIC that indicated higher risk associated with blood levels of stearic acid (32) .
On the other hand, our results sharply contrast with the literature on circulating MUFA levels and prostate cancer risk. Our results for palmitoleic acid (16:1n-7) are in agreement with a positive association reported by Harvei and colleagues (38) but not with the null results reported by 3 other prospective nested case-control studies (32, 34, 35) . Likewise, the positive association between oleic acid (18:1n-9) levels and prostate cancer is consistent with a previous report from the Physicians' Health Study (14) , but it contrasts with all other previous nested case-control studies (32, 34, 35, 38) . We are unaware of previous studies relating levels of myristoleic acid (14:1n-5) to prostate cancer. An important consideration in comparing our results with previous studies is that we used whole blood, whereas most previous studies have used plasma (14, 32, 37) , serum (35, 38) , or erythrocyte (34, 39) levels. However, we have found previously that whole-blood fatty acid levels are highly correlated to each other (2) and that the relation of dietary fatty acids with erythrocyte levels is not different from their relation with plasma levels (3), which suggests that it is possible to directly compare our results with the existing literature. Another important consideration is that the time between blood draws was generally longer in our study than in the existing literature. This might be important, given that the results for palmitoleic acid tended to be stronger with longer follow-up time.
Our study has several strengths. First, blood samples were collected before prostate cancer diagnosis. The prospective design and high follow-up rates of the Physicians' Health Study cohort decrease the possibility that our findings could be result of bias. Moreover, the results became stronger after exclusion of the first 2, 5, or 9 years of follow-up, which suggests that reverse causation is not a plausible explanation for our findings. The large number of cases allowed us to examine these associations with sufficient statistical power for total prostate cancer and for major clinical groupings of the disease. The most important limitation of our study is that residual and unmeasured factors associated with blood fatty acid levels could be responsible for the observed associations. Nevertheless, we evaluated several variables as potential confounders and found that adjustment for the few variables associated with fatty acid levels and prostate cancer, including all the fatty acids previously associated with prostate cancer risk in this cohort (4, 5) , had minimal impact on the results.
In summary, we found that blood levels of palmitoleic (16: 1n-7) acid were associated with a higher incidence of prostate cancer, particularly of high-grade disease. We also found that 2 tagging SNPs in FASN (rs6502051 and rs4246444) previously related to lower prostate cancer mortality rate (11) are also associated with lower whole-blood levels of this fatty acid. The findings presented in the present article, together with our previous report and experimental data from others, strongly suggest that de novo lipogenesis is involved in the origin of clinically relevant prostate cancer. Further investigation of how this metabolic pathway is involved in prostate carcinogenesis is warranted. For men in the highest quintile of the specific fatty acid in comparison with men in the lowest quintile. c Calculated with median fatty acid concentration in each quintile as a continuous variable.
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